Madeleine Durbeej-Hjalt
1 – 20 of 63
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Skeletal muscle regeneration is altered in the R6/2 mouse model of Huntington’s disease
2022) p.1-23(
- Working paper/Preprint › Preprint in preprint archive
- 2021
-
Mark
A guide to the composition and functions of the extracellular matrix
(
- Contribution to journal › Article
-
Mark
Merosin deficient congenital muscular dystrophy type 1A : An international workshop on the road to therapy 15-17 November 2019, Maastricht, the Netherlands
(
- Contribution to journal › Article
- 2020
-
Mark
A Family of Laminin α2 Chain-Deficient Mouse Mutants : Advancing the Research on LAMA2-CMD
(
- Contribution to journal › Scientific review
-
Mark
Antioxidants reduce muscular dystrophy in the dy2J/dy2J mouse model of laminin α2 chain-deficient muscular dystrophy
(
- Contribution to journal › Article
- 2019
-
Mark
A mutation-independent approach for muscular dystrophy via upregulation of a modifier gene
(
- Contribution to journal › Letter
-
Mark
Effects of N-acetyl-L-cysteine and vitamin E on congenital muscular dystrophy type 1A disease progression in mice
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
- 2018
-
Mark
Effects of metformin on congenital muscular dystrophy type 1A disease progression in mice: a gender impact study
2018) In Scientific Reports(
- Contribution to journal › Article
-
Mark
Laminin α1 reduces muscular dystrophy in dy2Jmice
(
- Contribution to journal › Article
-
Mark
Exploratory Profiling of Urine MicroRNAs in the dy2J/dy2J Mouse Model of LAMA2-CMD : Relation to Disease Progression
(
- Contribution to journal › Article
- 2017
-
Mark
Bioenergetic Impairment in Congenital Muscular Dystrophy Type 1A and Leigh Syndrome Muscle Cells
(
- Contribution to journal › Article
-
Mark
Potent pro-inflammatory and profibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chaindeficient muscular dystrophy
(
- Contribution to journal › Article
-
Mark
Absence of microRNA-21 does not reduce muscular dystrophy in mouse models of LAMA2-CMD
(
- Contribution to journal › Article
- 2016
-
Mark
Bortezomib Does Not Reduce Muscular Dystrophy in the dy2J/dy2J Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy.
(
- Contribution to journal › Article
-
Mark
212th ENMC International Workshop:: Animal models of congenital muscular dystrophies, Naarden, The Netherlands, 29-31 May 2015.
(
- Contribution to journal › Article
- 2015
-
Mark
Deletion of integrin α7 subunit does not aggravate the phenotype of laminin α2 chain-deficient mice.
(
- Contribution to journal › Article
-
Mark
Dystrophin deficiency reduces atherosclerotic plaque development in ApoE-null mice.
(
- Contribution to journal › Article
-
Mark
Laminin-α2 Chain-Deficient Congenital Muscular Dystrophy: Pathophysiology and Development of Treatment.
(
- Contribution to journal › Article
- 2014
-
Mark
Laminin α2 Chain-Deficiency is Associated with microRNA Deregulation in Skeletal Muscle and Plasma.
(
- Contribution to journal › Article
-
Mark
Bortezomib Partially Improves Laminin α2 Chain-Deficient Muscular Dystrophy.
(
- Contribution to journal › Article